Clin2
NCT02919644Possibly a fitRecruiting

Cancer vaccine made from your own cells after bowel cancer surgery

Stage IV Colorectal CancerCurative Resection

Part of Cancer, Digestive system clinical trials.

This trial tests whether a personalized vaccine—made from your own immune cells mixed with your own tumor material—can help prevent colorectal cancer from coming back after curative surgery. It may help your immune system recognize and fight any remaining cancer cells.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
19 people
Ages
19 years and older
Study type
Interventional

Who can take part

  • You have stage IV colorectal cancer that was fully removed with surgery intended to cure.
  • Your removed tissue must be collected and successfully processed at their lab to meet strict quality rules.
  • Recent scans (CT or MRI) within 60 days show no signs of cancer; if cancer was in other places before, those areas must be included in the scan.
  • You must have recovered well from surgery and prior treatment side effects (no significant ongoing problems from surgery).
  • You must be age 18 or older and well enough to do daily activities (performance status 0–1).
  • Blood tests and organ tests must be within acceptable ranges; heart function must be checked if you are 70 or older.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04166006Recruiting· Phase 2
Vaccine made from your tumor cells after surgery for rare cancers

This trial tests a personalized vaccine made from your own tumor material, aiming to lower the chance cancer returns after surgery. It is for people whose rare cancers have been removed completely and who have no standard treatment available after surgery.

Meldola, FC
NCT06522919Recruiting· Phase 2
Immunotherapy and chemotherapy for advanced colorectal cancer

This trial tests a sequence of treatments for people with a specific type of advanced colorectal cancer (called pMMR or MSS) that has not responded to earlier therapies. Patients first receive an immunotherapy combination (pembrolizumab plus a personalized dendritic cell vaccine) followed by a chemotherapy pill (trifluridine/tipiracil) plus bevacizumab. The goal is to see if this sequence can help control the cancer.

Meldola, Forlì Cesena
NCT04523688Recruiting· Phase 2
Dendritic cell vaccine made from your own tumor cells

This Phase 2 study tests a personalized glioblastoma vaccine made from your own immune cells (collected by apheresis) and your own tumor material. It’s meant to help your immune system recognize and attack the cancer after standard chemotherapy and radiation.

Meldola, FC
NCT06545630Recruiting· Phase 1
Personalized immune cell vaccine for colorectal cancer with liver spread

This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize colorectal cancer. It is for people who had surgery for colorectal cancer that spread to the liver and are now at high risk for the cancer returning.

Chengdu, Chengdu/Sichuan
NCT00722228Recruiting· Phase 1/Phase 2
Cancer vaccine made from your cells or a donor

This early-phase trial tests a whole-cell cancer vaccine for people with certain metastatic cancers. It aims to help your immune system recognize and fight the cancer, especially when prior chemotherapy hasn’t worked.

Jerusalem
NCT06530303Recruiting· Phase 1/Phase 2
Personalized immune cell therapy for colorectal cancer

This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.

Beijing, Beijing Municipality

Hear when a new Stage IV Colorectal Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.